Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prabhavathi Fernandes

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|November 6, 2013
Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep modelJeffrey A Keelan, Matthew W Kemp, Matthew S Payne, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2012
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearanceJürgen B Bulitta, Olanrewaju O Okusanya, Alan Forrest, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infectionsJ Carl Craft, Susan R Moriarty, Kay Clark, et al.
Science Translational Medicine|October 20, 2020
Prospects for a safe COVID-19 vaccineBarton F Haynes, Lawrence Corey, Prabhavathi Fernandes, et al.
Cell Host & Microbe|November 5, 2020
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 TherapeuticsJay A Grobler, Annaliesa S Anderson, Prabhavathi Fernandes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2016
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial PneumoniaThomas M File, Barbara Rewerska, Violeta Vucinic-Mihailovic, et al.
Schizophrenia Research|May 1, 2007
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophreniaMark S George, Christine E Molnar, Emily L Grenesko, et al.
Schizophrenia Research|June 29, 2007
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophreniaQiwen Mu, Kevin Johnson, Paul S Morgan, et al.
Antimicrobial Agents and Chemotherapy|February 18, 2016
Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in AdolescentsDaniel Gonzalez, Debra L Palazzi, Leena Bhattacharya-Mithal, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|November 6, 2013
Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep modelJeffrey A Keelan, Matthew W Kemp, Matthew S Payne, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2012
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearanceJürgen B Bulitta, Olanrewaju O Okusanya, Alan Forrest, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infectionsJ Carl Craft, Susan R Moriarty, Kay Clark, et al.
Science Translational Medicine|October 20, 2020
Prospects for a safe COVID-19 vaccineBarton F Haynes, Lawrence Corey, Prabhavathi Fernandes, et al.
Cell Host & Microbe|November 5, 2020
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 TherapeuticsJay A Grobler, Annaliesa S Anderson, Prabhavathi Fernandes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2016
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial PneumoniaThomas M File, Barbara Rewerska, Violeta Vucinic-Mihailovic, et al.
Schizophrenia Research|May 1, 2007
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophreniaMark S George, Christine E Molnar, Emily L Grenesko, et al.
Schizophrenia Research|June 29, 2007
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophreniaQiwen Mu, Kevin Johnson, Paul S Morgan, et al.
Antimicrobial Agents and Chemotherapy|February 18, 2016
Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in AdolescentsDaniel Gonzalez, Debra L Palazzi, Leena Bhattacharya-Mithal, et al.
Pageof 6